Symphogen Announces The Appointment Of Jeffrey H. Buchalter And Christoffer Søderberg As Non-Executive Directors
COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today the appointment to the company’s Board of Directors two new Non-Executive Directors: Mr. Jeffrey H. Buchalter and Mr. Christoffer Søderberg, effective 10 May 2016.